As ~90% of PCs are dependent on AR signaling at diagnosis [1], ADT initially inhibits cancer cell proliferation by lowering circulating testosterone concentrations, but ~10–20% of cases will progress and develop castration-resistant prostate cancer (CRPC) within 5 years [2]. Here, AR is linked to cancer.